HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.87.

HCM has been the topic of several analyst reports. Weiss Ratings downgraded HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Morgan Stanley set a $13.60 target price on shares of HUTCHMED in a report on Thursday, May 28th. HSBC raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. Bank of America lowered their target price on HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Daiwa Securities Group upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Thursday, September 3rd.

HUTCHMED Trading Down 3.3%

Shares of NASDAQ HCM opened at $13.90 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.64 and a debt-to-equity ratio of 0.06. HUTCHMED has a 1-year low of $9.77 and a 1-year high of $16.40. The business has a 50-day moving average of $12.48 and a 200-day moving average of $12.64.

HUTCHMED (NASDAQ:HCM) last posted its earnings results on Thursday, July 30th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The firm had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. As a group, equities analysts anticipate that HUTCHMED will post 0.23 EPS for the current year.

Institutional Trading of HUTCHMED

A number of large investors have recently added to or reduced their stakes in HCM. XY Capital Ltd boosted its position in shares of HUTCHMED by 115.2% in the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after purchasing an additional 55,736 shares during the period. Amundi boosted its position in HUTCHMED by 4.0% during the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in HUTCHMED in the first quarter worth approximately $365,000. 8.82% of the stock is currently owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines drug research and development capabilities with commercial operations in China and international markets.

HUTCHMED’s oncology portfolio includes fruquintinib, marketed in China as Elunate and in the United States as Fruzaqla for certain patients with metastatic colorectal cancer. The company also develops other targeted therapies, including savolitinib, a MET tyrosine kinase inhibitor, and surufatinib, an angiogenesis and immunomodulatory therapy.